ProfileGDS5678 / 1437313_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 97% 98% 97% 97% 97% 97% 96% 96% 97% 97% 97% 97% 97% 97% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 19.4773897
GSM967853U87-EV human glioblastoma xenograft - Control 29.8549998
GSM967854U87-EV human glioblastoma xenograft - Control 39.5887997
GSM967855U87-EV human glioblastoma xenograft - Control 49.8035497
GSM967856U87-EV human glioblastoma xenograft - Control 59.3823897
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 19.4119797
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.8287296
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.9129696
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 49.0840797
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 19.5217797
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 29.2082397
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 39.7104797
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 49.1172897
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 59.6396597